NCT00614458View on ClinicalTrials.gov

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
HIV Infections
Interventions
DRUG

Raltegravir; valproic acid

raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily

Trial Locations (1)

27599

University of North Carolina at Chapel Hill, Chapel Hill

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Abbott

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT00614458 - MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection | Biotech Hunter | Biotech Hunter